Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Maccubbin

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Cancer Research|July 15, 1992
Tumoricidal activation of murine resident peritoneal macrophages by interleukin 2 and tumor necrosis factor alphaS Verstovsek, D Maccubbin, M J Ehrke, et al.
International Journal of Clinical Practice|March 26, 2013
Effects of niacin on the incidence of new onset diabetes and cardiovascular events in patients with normoglycaemia and impaired fasting glucoseV Sazonov, D Maccubbin, C McCrary Sisk, et al.
Lymphokine and Cytokine Research|April 1, 1994
TNF-alpha potentiation of the lymphokine-activated killer response of murine thymus cellsP Ujházy, D Maccubbin, C Eppolito, et al.
International Journal of Immunopharmacology|January 1, 1987
Low concentrations of thymidine modulate allogeneic responsesL Strzadala, D Maccubbin, K Ryoyama, et al.
International Journal of Clinical Practice|March 16, 2011
Extended-release niacin/laropiprant lipid-altering consistency across patient subgroupsH Bays, A Shah, Q Dong, et al.
Cancer Immunology, Immunotherapy : CII|June 1, 1995
Protective specific immunity induced by cyclophosphamide plus tumor necrosis factor alpha combination treatment of EL4-lymphoma-bearing C57BL/6 miceC M Krawczyk, S Verstovsek, P Ujházy, et al.
Cancer Research|January 1, 1986
Correlation between adriamycin-induced augmentation of interleukin 2 production and of cell-mediated cytotoxicity in miceM J Ehrke, D Maccubbin, K Ryoyama, et al.
International Journal of Clinical Practice|June 20, 2008
Safety and efficacy of ezetimibe monotherapy in 1624 primary hypercholesterolaemic patients for up to 2 yearsC A Dujovne, R Suresh, C McCrary Sisk, et al.
Oncology Research|January 1, 1993
Development of a safe and effective adriamycin plus interleukin 2 therapy against both adriamycin-sensitive and -resistant lymphomasR L Ho, D Maccubbin, G Zaleskis, et al.
Cancer Research|June 1, 1987
Effect of recombinant human tumor necrosis factor on the induction of murine macrophage tumoricidal activityK Hori, M J Ehrke, K Mace, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Cancer Research|July 15, 1992
Tumoricidal activation of murine resident peritoneal macrophages by interleukin 2 and tumor necrosis factor alphaS Verstovsek, D Maccubbin, M J Ehrke, et al.
International Journal of Clinical Practice|March 26, 2013
Effects of niacin on the incidence of new onset diabetes and cardiovascular events in patients with normoglycaemia and impaired fasting glucoseV Sazonov, D Maccubbin, C McCrary Sisk, et al.
Lymphokine and Cytokine Research|April 1, 1994
TNF-alpha potentiation of the lymphokine-activated killer response of murine thymus cellsP Ujházy, D Maccubbin, C Eppolito, et al.
International Journal of Immunopharmacology|January 1, 1987
Low concentrations of thymidine modulate allogeneic responsesL Strzadala, D Maccubbin, K Ryoyama, et al.
International Journal of Clinical Practice|March 16, 2011
Extended-release niacin/laropiprant lipid-altering consistency across patient subgroupsH Bays, A Shah, Q Dong, et al.
Cancer Immunology, Immunotherapy : CII|June 1, 1995
Protective specific immunity induced by cyclophosphamide plus tumor necrosis factor alpha combination treatment of EL4-lymphoma-bearing C57BL/6 miceC M Krawczyk, S Verstovsek, P Ujházy, et al.
Cancer Research|January 1, 1986
Correlation between adriamycin-induced augmentation of interleukin 2 production and of cell-mediated cytotoxicity in miceM J Ehrke, D Maccubbin, K Ryoyama, et al.
International Journal of Clinical Practice|June 20, 2008
Safety and efficacy of ezetimibe monotherapy in 1624 primary hypercholesterolaemic patients for up to 2 yearsC A Dujovne, R Suresh, C McCrary Sisk, et al.
Oncology Research|January 1, 1993
Development of a safe and effective adriamycin plus interleukin 2 therapy against both adriamycin-sensitive and -resistant lymphomasR L Ho, D Maccubbin, G Zaleskis, et al.
Cancer Research|June 1, 1987
Effect of recombinant human tumor necrosis factor on the induction of murine macrophage tumoricidal activityK Hori, M J Ehrke, K Mace, et al.
Pageof 2